SLC5A2 and cardiac arrhythmia: Although there is evidence for a reduction in new-onset arrhythmic events in patients treated with SGLT2-i, previous studies yielded inconclusive results and a variable association between SGLT2-i treatment and cardiac arrhythmias (22–24).